Dexrazoxane Side Effects
Brand Names: Totect, Zinecard
Please note - some side effects for Dexrazoxane may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
Side Effects of Dexrazoxane - for the Consumer
Dexrazoxane
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Dexrazoxane:
Seek medical attention right away if any of these SEVERE side effects occur when using Dexrazoxane:Diarrhea; difficulty swallowing; fever; general body discomfort; hair loss; infection (chills; sore throat); loss of appetite; nausea; pain or swelling at the injection site; streaking or flushing of the skin; swelling of the throat or tongue; tiredness; vomiting.
TopSevere allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
Dexrazoxane Side Effects - for the Professional
Dexrazoxane
Dexrazoxane at a dose of 500 mg/m2 has been administered in combination with FAC in randomized, placebo-controlled, double-blind studies to patients with metastatic breast cancer. The dose of doxorubicin was 50 mg/m2 in each of the trials. Courses were repeated every three weeks, provided recovery from toxicity had occurred. Table 2 below lists the incidence of adverse experiences for patients receiving FAC with either Dexrazoxane or placebo in the breast cancer studies. Adverse experiences occurring during courses 1 through 6 are displayed for patients receiving Dexrazoxane or placebo with FAC beginning with their first course of therapy (column 1 & 3, respectively). Adverse experiences occurring at course 7 and beyond for patients who received placebo with FAC during the first six courses and who then received either Dexrazoxane or placebo with FAC are also displayed (column 2 & 4, respectively).
| ADVERSE EXPERIENCE | PERCENTAGE (%) OF BREAST CANCER PATIENTS WITH ADVERSE EXPERIENCE | |||
| FAC + Dexrazoxane | FAC + PLACEBO | |||
| Courses 1-6 N = 413 |
Courses ≥7 N = 102 |
Courses 1-6 N = 458 |
Courses ≥7 N = 99 |
|
| Alopecia | 94 | 100 | 97 | 98 |
| Nausea | 77 | 51 | 84 | 60 |
| Vomiting | 59 | 42 | 72 | 49 |
| Fatigue/Malaise | 61 | 48 | 58 | 55 |
| Anorexia | 42 | 27 | 47 | 38 |
| Stomatitis | 34 | 26 | 41 | 28 |
| Fever | 34 | 22 | 29 | 18 |
| Infection | 23 | 19 | 18 | 21 |
| Diarrhea | 21 | 14 | 24 | 7 |
| Pain on Injection | 12 | 13 | 3 | 0 |
| Sepsis | 17 | 12 | 14 | 9 |
| Neurotoxicity | 17 | 10 | 13 | 5 |
| Streaking/Erythema | 5 | 4 | 4 | 2 |
| Phlebitis | 6 | 3 | 3 | 5 |
| Esophagitis | 6 | 3 | 7 | 4 |
| Dysphagia | 8 | 0 | 10 | 5 |
| Hemorrhage | 2 | 3 | 2 | 1 |
| Extravasation | 1 | 3 | 1 | 2 |
| Urticaria | 2 | 2 | 2 | 0 |
| Recall Skin Reaction | 1 | 1 | 2 | 0 |
The adverse experiences listed above are likely attributable to the FAC regimen with the exception of pain on injection that was observed mainly on the Dexrazoxane arm.
Myelosuppression
Patients receiving FAC with Dexrazoxane experienced more severe leukopenia, granulocytopenia and thrombocytopenia at nadir than patients receiving FAC without Dexrazoxane, but recovery counts were similar for the two groups of patients.
Hepatic and Renal
Some patients receiving FAC + Dexrazoxane or FAC + placebo experienced marked abnormalities in hepatic or renal function tests, but the frequency and severity of abnormalities in bilirubin, alkaline phosphatase, BUN, and creatinine were similar for patients receiving FAC with or without Dexrazoxane.
TopSide Effects by Body System
Gastrointestinal
Gastrointestinal side effects including nausea (43%), vomiting (19%), diarrhea (11%), abdominal pain (6%), and constipation (6%) have been reported.
General
General side effects including pyrexia (21%), postoperative infection (16%), fatigue (13%), peripheral edema (10%), chest pain, chest discomfort, decreased drug effect, hyperpyrexia, and decreased therapeutic response have been reported.
Local
Local side effects including injection site pain (16%) and injection site phlebitis (6%) have been reported.
Cardiovascular
Cardiovascular side effects including vascular disorders (15%) and cardiac disorders (5%) have been reported.
Dermatologic
Dermatologic side effects including alopecia (14%) have been reported.
Musculoskeletal
Musculoskeletal side effects including "musculoskeletal and connective tissue disorders" (13%) have been reported.
Nervous system
Nervous system side effects including dizziness (11%) and headache (6%) have been reported.
Respiratory
Respiratory side effects including dyspnea (8%), pneumonia (6%), and cough (5%) have been reported.
Psychiatric
Psychiatric side effects including depression (8%), anorexia (5%), and insomnia (5%) have been reported.
Hematologic
Hematologic side effects including anemia (6%), decreased WBC, decreased neutrophils, and decreased platelets have been reported.
Hepatic
Hepatic side effects including increased bilirubin, increased AST, increased ALT, increased alkaline phosphatase, and increased LDH have been reported
Metabolic
Metabolic side effects including increased creatinine, decreased sodium, and increased total calcium have been reported.
TopMore Dexrazoxane resources
- dexrazoxane Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
- Dexrazoxane Prescribing Information (FDA)
- Dexrazoxane Professional Patient Advice (Wolters Kluwer)
- Dexrazoxane Medfacts Consumer Leaflet (Wolters Kluwer)
- Totect Consumer Overview
- Totect Prescribing Information (FDA)
- Zinecard Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
